Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology, Rheumatology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jan 1, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.187, Nipocalimab-aahu (Imaavy)

Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy

Effective date

Jan 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.187 has been created for Nipocalimab-aahu (Imaavy), a specialty pharmacy drug. This establishes coverage and billing guidelines for this medication effective January 1, 2026.

Action Required

Action needed

Before January 1, 2026: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Nipocalimab-aahu (Imaavy). Update drug formulary references and inform providers about the new medication coverage guidelines.

Related policy hubs

Independence Blue Cross policies Oncology Hematology Rheumatology